Source: European Medicines Agency (EU) Revision Year: 2017 Publisher: Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom
Zontivity 2 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. The film-coated tablets are yellow, oval-shaped, size 8.48 mm x 4.76 mm, with “351” on one side and the MSD logo on the other side. |
Each film-coated tablet contains 2.08 mg of vorapaxar (as vorapaxar sulfate).
Excipient(s) with known effect: Each film-coated tablet contains 66.12 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Vorapaxar |
Vorapaxar is a selective and reversible inhibitor of the PAR-1 receptors on platelets that are activated by thrombin. |
| List of Excipients |
|---|
|
Tablet core: Lactose monohydrate Film coating: Lactose monohydrate |
Packs of 7, 28, 30 and 100 film-coated tablets in aluminium/aluminium blister cards.
Packs of 10 and 50 film-coated tablets in aluminium/aluminium unit-dose blister cards.
Not all pack sizes may be marketed.
Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom
EU/1/14/976/001
EU/1/14/976/002
EU/1/14/976/003
EU/1/14/976/004
EU/1/14/976/005
EU/1/14/976/006
Date of first authorisation:19 January 2015
| Drug | Countries | |
|---|---|---|
| ZONTIVITY | Estonia, Lithuania, Romania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
